Objective: Impaired quality of life (QoL) in primary hyperparathyroidism (PHPT) is commonly present. Patients may complain about nonspecific neurocognitive symptoms which can be difficult to quantify. Two different disease-specific questionnaires have been developed, that is, the parathyroid assessment of symptoms score (PAS) and the primary hyperparathyroidism quality of life (PHPQoL). Using these two questionnaires, we assessed relationship between QoL and biochemical indices in PHPT and effects of parathyroidectomy (PTX).
| INTRODUC TI ON
The clinical presentation of primary hyperparathyroidism (PHPT) has changed since the introduction of multichannel biochemistry.
1 Today,
PHPT is often diagnosed in earlier stages of the disease with only mild symptoms and complications. 1, 2 Even though the clinical presentation of PHPT has changed to become less symptomatic, patients may still complain about nonspecific neurocognitive symptoms such as poor concentration, fatigue, anxiety, mood swings, depression and cognitive decline. 3, 4 However, these nonspecific symptoms are difficult to quantify, and it is unclear to what extent these symptoms are related to PHPT and whether parathyroidectomy (PTX) relieves the symptoms. Most studies, so far, have evaluated health-related quality of life (HRQoL) in PHPT using non-disease-specific questionnaire such as the Short Form-36 (SF-36) general health survey. [5] [6] [7] [8] [9] [10] [11] [12] [13] Four randomized clinical trials (RCTs) assessed HRQoL in asymptomatic PHPT patients, including effect of parathyroidectomy (PTX). Three studies showed a modest improvement in different areas of QoL after PTX, whereas ambiguous results were observed in the fourth RCT. [14] [15] [16] [17] Disease-specific surveys have been developed as a tool to evaluate the symptoms and impact on HRQoL of PHPT as well as effects of PTX. The parathyroid assessment of symptoms score (PAS) is a questionnaire based on a visual analog scale (VAS) that focuses on the severity of symptoms commonly reported by patients with PHPT. 18 Prospective studies have observed a significant decrease in symptom score 12 months after PTX. 10, 19, 20 Additionally, a disease-specific questionnaire named primary hyperparathyroidism quality of life (PHPQoL) was recently developed. 21 So far, only one prospective study has evaluated the PHPQoL in 104 PHPT patients and observed a significant improvement in QoL 3 months after PTX. 22 At the fourth International workshop on asymptomatic Fourth
International Workshop on Asymptomatic PHPT, more information on neuropsychiatric and cognitive function was requested.
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The aim of this study was to investigate the relationship between PAS and PHPQoL and biochemical indices in patients with PHPT, furthermore, to evaluate any beneficial effects of parathyroidectomy on health-related quality of life assessed by PAS and PHPQoL.
| SUBJEC TS AND ME THODS
Patients with PHPT were referred to Aarhus University Hospital for evaluation of the indications for PTX. We enrolled patients referred from 1 January 2015 to 1 March 2017 allowing for 1 year of follow after PTX (Figure 1 ). We only included patients who fulfilled the diagnostic biochemical criteria for PHPT with ionized calcium above upper limit of reference range and parathyroid hormone (PTH) in the upper third or above upper limit of reference range (mean of two measurements). Patients with a history of chronic kidney disease, multiple endocrine neoplasia, previous neck surgery and parathyroid cancer were excluded. Based on a 24-hour urine collection, patients with a calcium to creatinine clearance ratio (CCCR) <0.02 were genetically tested for familial hypocalciuric hypercalcemia (FHH) type I and III and excluded if diagnosed with an inactivating mutation.
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A group of patients were excluded before follow-up due to either persistent hypercalcemia, hypoparathyroidism or severe illness or distress, for example, cancer and loss of partner (17%; Figure 1 ). 
| Questionnaires
Included patients were asked to answer the PAS and PHPQoL The PAS questionnaire comprises 13 items which represent commonly occurring symptoms in PHPT quantified on a VAS score from 0 (no symptoms) to 100 (feeling of the most extreme aspect of the symptom). 18 A summary is calculated based on the sum of all 13
answers ranging from 0 to 1300. The 13 items include the following: feeling tired easily, feeling week, pains in the bones, joint pains, being forgetful, having mood swings, being thirsty, feeling irritable, feeling "blue" or depressed, itchy skin, difficulties getting out of a chair or car, headache and stomach ache.
The PHPQoL questionnaire comprises of 16 items (Table 1) in which answers to each item are ranging from 0 to 4 in terms of "always" = (0), "many times" = (1), "from time to time" = (2), "hardly ever" = (3) and "never" = (4). The time perspective is how often the patient has experienced the symptoms during the past four weeks. Of notice, a higher score equals a better HRQoL. The total score (range 0-64) is standardized to a scale between 0 and 100 by the formula: (obtained score − minimum score)/(maximum score − minimum score) × 100. 
| Ethics
The study was approved by The Danish Health and Medicines
Authority granted access to retrieve data from hospital charts 
| Statistics

| RE SULTS
A total of 139 PHPT patients received the questionnaires among whom 104 patients answered PAS and PHPQoL questionnaires at time of diagnosis. 
| Preoperative QOL
| Postoperative follow-up
A total of 94 (90%) patients from the initial group underwent PTX from 2015 to 2017 among whom 53 (56%) answered PAS and
PHPQoL questionnaires one year after PTX, whereas 25 (27%) were lost to follow-up as they did not return surveys ( Figure 1 ).
As shown in Table 3 No correlations between percentage change in total PHPQoL score from baseline to end of follow-up and levels of ionized calcium and PTH (baseline values) were observed (data not shown).
| Characteristics of patients with PHPT not returning the questionnaires
Among the 94 patients with PHPT who had PTX performed, 25 (27%) patients did not return the questionnaires. Overall, characteristics of patients lost to follow-up did not differ from those who did return questionnaires, except for eGFR which were significantly (P ˂ 0.01) higher among patients lost to follow-up.
| D ISCUSS I ON
This is the first evaluation of disease-specific questionnaires in a Danish cohort of patients with PHPT. We identified feeling tired, weak, forgetful and depressed as the most frequent symptoms.
We observed improved HRQoL as assessed by PAS and PHPQoL 12 months after PTX which were seen for patients with both mild and moderate-severe hypercalcemia. At baseline, PHPQoL score was inversely associated with ionized calcium and did not change after multiple adjustments. Patients with moderate-severe hypercalcemia had lower (worse) HRQoL assessed by PHPQoL compared to patients with mild hypercalcemia. We found no relationship between the presence of organ manifestations and PAS and PHPQoL scores at baseline.
With the changing clinical presentation of PHPT with more subtle symptoms, the possible benefit of PTX on HRQoL has been questioned. 1 The PHPQoL is a recently developed tool to assess HRQoL in PHPT. The PHPQoL quantifies the impact on HRQoL across two domains: physical and emotional/neuropsychological functions in PHPT.
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The potential benefit of using a disease-specific survey is the ability to quantify symptoms of specific importance to patients' daily living.
This opposed to the SF-36 survey which assesses health and well-being in general terms. 25 Only one observational study has examined the PHPQoL questionnaire among 104 patients with PHPT. A mean score of 52 (±23) was reported at baseline with an improvement in total score to 61 (±22) 3 months after PTX. Total PHPQoL remained stable at 6
and 12 months and did not improve further. In our study, the median PHPQoL score at time of diagnosis was higher (75 ) compared with the previous study and did not improve to the same magnitude (79 [39-95]) following PTX. 22 However, a possible explanation for the less pronounced increase in our study may be a tendency for better HRQoL at baseline. Even though total PHPQoL score was higher in our population, we still found a significantly improved QoL 12 months after PTX.
Additionally, we did not observe any differences in PHPQoL between symptomatic and asymptomatic patients. This is in contrast to Webb et al 22 reporting lower PHPQoL score (worse) in symptomatic compared to asymptomatic patients defined according to international guidelines for recommendation of PTX including symptomatic complains likely attributable to PHPT. 24 However, we did not have any information about symptomatic complaints and therefore only classified patients as symptomatic or asymptomatic according to levels of ionized calcium, age and organ manifestations attributable to PHPT. Furthermore, the degree of PHPT was less severe in this cohort than the initially described patients, who presumably also had more prevalent symptoms. This is only the second study evaluating PHPQoL questionnaire in a clinical setting, and further studies are needed to explore the validity of PHPQoL in clinical practice.
The PAS questionnaire is another disease-specific tool developed items. This is in contrast to some other studies reporting improvement in all 13 items. 10, 19 Again, this may be explained by the better PAS score at baseline in our study group, reflecting a less intense degree of PHPT.
We found a significantly different PHPQoL score between patients with mild and moderate-severe hypercalcemia at baseline and also a significantly improved PHPQoL score (better) within the group of patients with mild and moderate-severe hypercalcemia from baseline to end of follow-up. However, we did not observe any differences in PAS score according to levels of ionized calcium at baseline or to end of follow-up. This may suggest that PHPQoL questionnaire is more sensitive at quantifying PHPT-related symptoms especially among patients with mild hypercalcemia. However, further studies are needed evaluating PAS and PHPQoL questionnaires in PHPT and possible effect of PTX.
We observed inverse correlations between PHPQoL score at baseline and ionized calcium and PTH. This may suggest that levels of ionized calcium are of importance to HRQoL. In three other studies, a positive correlation between serum calcium and depression symptoms has been reported. [29] [30] [31] Unfortunately, our study was not designed to explore mechanisms. However, it is well known that calcium levels normally are tightly regulated and our findings point towards adverse effects of even mild hypercalcemia on well-being.
In contrast to the PHPQoL findings, we did not observe any correlations between PAS score and biochemical indices. Furthermore, we did not observe any relationship of the changes in total PHPQoL and PAS score from baseline to end of follow-up and levels of ionized calcium. This is in accordance with most other studies 9, 10, 19, 20, 22, 32 which report no correlations between QoL and biochemical indices in PHPT. Individual patients may have very different thresholds for well-being and QoL. However, we did find a significantly higher (better) PHPQoL score in patients with mild compared to patients with TA B L E 3 Characteristics of patients with primary hyperparathyroidism before and 1 year after surgery. Number of subjects (%) or median with interquartile (25%-75%) range 
| Strengths and limitations
It is a strength to our study that we used disease-specific validated questionnaires to assess HRQoL in PHPT. 18, 22 Thus, we used tools to evaluate the common, although nonspecific neurocognitive symptoms prevalent in PHPT and the effect of PTX. Furthermore, we included PHPT patients with the most common clinical presentation of PHPT today.
There are some limitations to this study. It is not a RCT, and PTX was offered to all patients fulfilling the diagnostic criteria for PHPT. It is therefore possible that the improvement in HRQoL may be a placebo effect of surgery, that is, patients may feel better solely due to the fact that they are told that they have been cured. We did not include the SF-36 survey and can therefore not compare with most other studies assessing HRQoL in PHPT. Furthermore, we did not have a control group and can therefore not compare PAS and PHPQoL score to the general background population which, however, being a disease-specific instrument, is methodologically difficult. It is also a limitation that we did not have any history of subjective symptomatic complains apart from the questionnaires.
In addition, 27% were lost to follow-up (did not return the surveys) which may bias the results. However, patients lost to follow-up did not differ significantly from patients returning the questionnaires.
Importantly, further studies are needed to test the validity and usefulness of the questionnaires used in this study in order to determine their potential usefulness in clinical practice.
| CON CLUS ION
We observed improved HRQoL in PHPT patients 12 months after PTX which support the notion that patients with PHPT benefit from PTX despite mild disease. Impaired QoL seems to be associated with levels of ionized calcium, whereas organ manifestation attributable to PHPT seems less important for HRQoL. Moreover, PHPQoL seems to be a valid tool to evaluate HRQoL in PHPT. Further studies using the disease-specific PAS and PHPQoL questionnaires are needed to elucidate the involvement of nonspecific neurocognitive symptoms in PHPT and effects of PTX.
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